aMoon Fund

Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.

Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.

Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.

Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

MOBILion Systems, Inc. is a biotechnology company focused on advancing the detection and analysis of clinically relevant molecules that conventional instruments struggle to identify. The company has developed structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations and enable researchers to detect minute traces of disease-specific biomolecules. Founded in 2015 and based in Chadds Ford, Pennsylvania, MOBILion's technology enhances the sensitivity, resolution, and throughput of analytical instruments. This innovation supports the identification of biologic therapeutics, accelerates biomarker discovery, and improves the accuracy of diagnostic tests. By processing large-scale samples efficiently, MOBILion aims to contribute to better disease prediction, diagnosis, and treatment, ultimately empowering clinicians and researchers to address diseases at their core rather than merely treating symptoms.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, that focuses on using gut microbiome analysis to provide personalized health solutions for metabolic diseases such as diabetes, prediabetes, and obesity. Founded in 2015, the company utilizes gut microbiome sequencing to create tailored Food Prescriptions™ that help individuals manage their blood sugar levels, improve energy, and achieve weight loss. Their digital platform offers actionable dietary recommendations based on individual biometrics and lifestyle factors, ensuring that patients receive insights that are practical and easy to follow. DayTwo also employs a telehealth service, where Certified Diabetes Care and Education Specialists and Registered Dietitians support patients through a smartphone application, allowing for progress tracking and communication. The effectiveness of DayTwo's approach is measured using clinical outcomes such as A1C levels and Time In Range, with the potential for full fee reimbursement for those who adhere to the protocol.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.

AltruBio is a biopharmaceutical company that specializes in developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. Founded in 2000, the company has its research and development base in Taipei, Taiwan, and operates globally with its principal office in the San Francisco Bay Area. AltruBio focuses on addressing unmet medical needs by discovering and developing innovative therapeutics. Its research scientists utilize a robust discovery platform to identify and validate new antibody treatments. The company has a promising pipeline of therapeutic antibodies aimed at various conditions, including autoimmune diseases and multiple types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancer, which are in various stages of development.

Samumed, LLC is a biopharmaceutical company focused on small molecule drug development aimed at oncology and degenerative diseases. Founded in 2007 and based in San Diego, California, the company utilizes its expertise in Wnt pathway modulation to create therapeutics for tissue-level regeneration. Among its key products are SM04690, an intra-articular injection for treating knee osteoarthritis, and SM07883, which is designed to mitigate disease pathology. Samumed is committed to advancing regenerative medicine through its innovative platform, which seeks to improve patient health by addressing a variety of degenerative conditions.

Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based systems for cancer diagnosis in pathology. The company's flagship product, the Ibex Second Read system, operates alongside human pathologists to analyze medical cases, identifying discrepancies between human diagnoses and its AI-driven analysis. By integrating artificial intelligence, data science, and image analysis with digitized glass slides and electronic medical records, Ibex aims to improve clinical decision-making and streamline pathology workflows. The technology is designed to reveal underlying patterns in data, providing valuable clinical insights that enhance the accuracy and speed of diagnoses. Ultimately, Ibex Medical Analytics is focused on advancing cancer care and improving patient outcomes and quality of life through innovative diagnostic solutions.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. The company aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health-tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. It contributes to making the global healthcare system more sustainable. By helping healthcare professionals leverage their expertise and work together as a community, patients can receive equal access to better diagnoses and treatments. It combines the first two pillars of data-driven medicine, genomics, and radionics, the company ensures that the data used to help patients. Founded by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, SOPHiA GENETICS was incorporated in 2011. It has offices in Boston, Massachusetts, Switzerland, and France.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

MiNA Therapeutics Limited, a biotechnology company, engages in the design and development of small activating RNA medicines that restore normal function to patients' cells. The company’s products in pipeline includes MTL-CEBPA + Sorafebib for hepatocelluar carcinoma; and MTL-CEBPA + Pembrolizumab for advanced solid tumors. The company was incorporated in 2008 and is based in London, United Kingdom.

MOBILion Systems, Inc. is a biotechnology company focused on advancing the detection and analysis of clinically relevant molecules that conventional instruments struggle to identify. The company has developed structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations and enable researchers to detect minute traces of disease-specific biomolecules. Founded in 2015 and based in Chadds Ford, Pennsylvania, MOBILion's technology enhances the sensitivity, resolution, and throughput of analytical instruments. This innovation supports the identification of biologic therapeutics, accelerates biomarker discovery, and improves the accuracy of diagnostic tests. By processing large-scale samples efficiently, MOBILion aims to contribute to better disease prediction, diagnosis, and treatment, ultimately empowering clinicians and researchers to address diseases at their core rather than merely treating symptoms.

Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.

Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies.

Curesponse, a diagnostics company, develops a tissue culture system for modelling cancer growth and drug response. The company develops an online platform for patients and clinicians to send samples of their tumor to be tested. Curesponse was founded in 2017 and is based in Tel Aviv-Yafo, Israel.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Apos Medical Assets Ltd. specializes in non-surgical orthopedic services, primarily through its innovative AposTherapy program. Founded in 2004 and based in New York, the company has expanded its operations to Israel, Singapore, and the United Kingdom. AposTherapy was developed by orthopedic and sports medicine experts in response to advancements in biomechanics and the neuromuscular system's role in orthopedic rehabilitation. The treatment involves a personalized program that uses a patented foot-worn biomechanical device, delivered by specially-trained physical therapists. Patients engage in the therapy during their daily activities for about an hour each day, addressing biomechanical abnormalities associated with various orthopedic conditions. AposTherapy aims to restore proper motor patterns and empower patients by enhancing their understanding of their conditions. The company monitors patient progress closely and shares clinical outcomes to provide objective measures of improvement. With over 50,000 patients treated worldwide and multiple research publications, AposHealth is committed to advancing knowledge and improving the quality of life for individuals with musculoskeletal disorders.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017. It specializes in developing advanced CRISPR solutions, including its proprietary DETECTR technology, which allows for the detection of specific nucleic acids in samples, aiding in diagnostics for various conditions such as bacterial infections, cancer, and viral infections. The company focuses on democratizing disease detection through accessible point-of-care tests that can simultaneously identify multiple health issues. Additionally, Mammoth offers CRISPR-Cas systems for genome editing, targeting therapeutic applications in immuno-oncology, autoimmune diseases, and liver diseases. Its innovative solutions are utilized across diverse sectors, including healthcare, agriculture, environmental monitoring, and biodefense. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is supported by notable institutional and individual investors, reflecting its commitment to harnessing CRISPR technology for significant advancements in life sciences.

NanoGhosts’ technology is based on its founder’s research, that the Technion's commercial unit has patented in the U.S. and Europe.

Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.

Vocalis Health is a health technology company based in Tel Aviv, Israel, with an additional office in the United States. Founded in 2019, the company specializes in developing an artificial intelligence-based platform that utilizes vocal biomarkers to monitor and diagnose health conditions through voice analysis. The technology enables healthcare providers to remotely interact with patients, facilitating screening and monitoring for various voice-affecting diseases, including chronic respiratory and cardiac conditions, as well as mental health issues such as depression. By leveraging machine learning and deep learning techniques, Vocalis Health's platform allows for the assessment of a patient's health status via voice recordings, providing insights that can help evaluate the severity or presence of specific health conditions.

Igentify Ltd is a company focused on preventive healthcare through genomic products and services, established in 2016 and headquartered in Haifa, Israel. The company offers FamilyFirst, an expanded carrier screening specifically designed for the Jewish and Israeli populations. Igentify operates a digital genetic platform that enhances accessibility and usability of genomic information for clinicians, laboratories, and patients. This platform addresses the increasing demand for genomic medicine by streamlining the process of genetic testing. It includes features such as digitizing genetic assistants, customizing educational resources, collecting consent, analyzing data, and providing tailored results through video. By simplifying these steps, Igentify enables test providers to efficiently gather necessary information from patients across various devices.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, that focuses on using gut microbiome analysis to provide personalized health solutions for metabolic diseases such as diabetes, prediabetes, and obesity. Founded in 2015, the company utilizes gut microbiome sequencing to create tailored Food Prescriptions™ that help individuals manage their blood sugar levels, improve energy, and achieve weight loss. Their digital platform offers actionable dietary recommendations based on individual biometrics and lifestyle factors, ensuring that patients receive insights that are practical and easy to follow. DayTwo also employs a telehealth service, where Certified Diabetes Care and Education Specialists and Registered Dietitians support patients through a smartphone application, allowing for progress tracking and communication. The effectiveness of DayTwo's approach is measured using clinical outcomes such as A1C levels and Time In Range, with the potential for full fee reimbursement for those who adhere to the protocol.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based systems for cancer diagnosis in pathology. The company's flagship product, the Ibex Second Read system, operates alongside human pathologists to analyze medical cases, identifying discrepancies between human diagnoses and its AI-driven analysis. By integrating artificial intelligence, data science, and image analysis with digitized glass slides and electronic medical records, Ibex aims to improve clinical decision-making and streamline pathology workflows. The technology is designed to reveal underlying patterns in data, providing valuable clinical insights that enhance the accuracy and speed of diagnoses. Ultimately, Ibex Medical Analytics is focused on advancing cancer care and improving patient outcomes and quality of life through innovative diagnostic solutions.

Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Nobio Ltd. is an Israel-based company that specializes in developing innovative nano-polymer additives designed to protect against microbial infections. Their technology offers a unique, fully-integrated anti-biofilm solution, utilizing potent particles embedded in various materials and products to inhibit biofilm formation indefinitely. Nobio's product line includes a universal bonding agent that provides strong adhesion for dental applications, as well as flowable composites suitable for various restorative procedures. By transforming both implantable and non-implantable devices into biofilm-resistant platforms, Nobio aims to enhance the safety and durability of medical and dental materials through its advanced antimicrobial technology.

Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Medial EarlySign Ltd is a healthcare technology company based in Kfar Malal, Israel, founded in 2009. The company specializes in developing AI-driven platforms designed to enhance clinical decision-making and disease management. Its primary offerings include AlgoMarkers and AlgoAnalyzer, predictive engines that utilize basic medical information, such as blood test results and electronic medical records, to identify risks associated with critical health threats. By analyzing extensive datasets from millions of patient records, Medial EarlySign aims to deliver actionable clinical insights that enable healthcare providers to predict outcomes related to cancers, metabolic, immune, and infectious diseases. These tools empower organizations to optimize care for individuals, facilitate proactive health management, and potentially reduce healthcare costs by improving patient outcomes and resource allocation.

Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.

Cartiheal Ltd., a medical device company, develops implants for the regeneration of cartilage and bone disorders. The company offers Agili-C, an off the shelf and cell-free implant that regenerates hyaline cartilage and its underlying subchondral bone. Its implant is used for the treatment of focal articular cartilage and osteochondral defects. The company was founded in 2009 and is based in Kfar Sava, Israel.